The mortality rate is high in patients receiving hemodialysis (HD), atherosclerotic diseases being the major cause of death. As marker of clinical outcome, a prospective examination of atherosclerotic tests and atherosclerotic risk factors in patients receiving HD was performed. On April 2000, 84 patients receiving HD were followed up until April 2002. At entry to the study, several atherosclerotic tests, including ankle-arm blood pressure index (API), aortic calcification index (ACI), and atherosclerotic risk factors, were performed. In 36 patients with old thrombotic events, 26 had new thrombotic events. Of 48 patients without previous thrombotic events, 15 had new thrombotic events. During 2 years, 41 patients had new thrombotic events and 15 patients died due to thrombotic disorders. The HD durations were significantly longer in non-survivors than survivors and the body mass index was lower in non-survivors than survivors. There was a significant difference in the values of ACI and API between survivors and non-survivors, and between patients with and without thrombotic events. These findings suggest that the ACI and API have a prognostic value because they might predict the occurrence of thrombosis.
Despite dramatic improvement in hemodialysis (HD) techniques, there is still high mortality among patients receiving HD; the mortality rate is 9.4% in Japan (1) and 23.5% in the United States (2) . Arteriosclerosis-associated diseases such as cerebrovascular disease (CVD) and cardiovascular disease (CAD) are the major cause of death in patients receiving HD. Several atherosclerotic risk factors including diabetes mellitus (DM) (3), abnormal lipid metabolism (4), hypertension (5) , obesity, age, and uremia-associated abnormalities of the hemostatic system (6, 7) play an important etiologic role in the pathogenesis of atherosclerosis in these patients. For screening of atherosclerosis, ankle-arm blood pressure index (API) and aortic calcification index (ACI) are often used. API (8) , which is the ratio of the ankle-to-arm systolic blood pressure, is used for assessing peripheral vascular disease such as atherosclerotic obliterance. Previous studies have shown that the presence of peripheral vascular disease is a strong predictor of mortality; API is a powerful predictor of CAD and overall mortality (9, 10) . ACI, which indicates organic changes in the vascular wall, is used as an index of the degree of complicated atheroscle-rotic plaque formation (11, 12) . Previous epidemiologic studies have shown that sclerotic aorta calcification reflects early arteriosclerosis and that it is correlated with coronary disease (13) . It has been reported that aortosclerosis is significantly accelerated in patients receiving chronic HD and that aortosclerotic changes are comparable to those observed in a 20-year older control (14) . In the present study, we prospectively evaluated the value of atherosclerotic tests and atherosclerotic risk factors to predict clinical outcome in patients receiving HD.
MATERIALS AND METHODS

Patients
This study comprised 84 patients (38 men and 46 women, age 64.8±9.8 years old, HD duration 6.60±5.75 years) receiving HD in the outpatient department of the Matsusaka Chuou Hospital. We consecutively admitted patients who had HD in the morning course on April 2000. At entry, none of the patients had acute infectious disease or were taking anticoagulant drugs and statins. Informed consent was obtained from all patients at the beginning of the study. These patients were observed from April 2000 through April 2002. At entry, all patients underwent several atherosclerotic and examined atherosclerotic risk factors. The patients were categorized in different groups as follows. Patients with a history of CAD, CVD, atherosclerotic obliterance, shunt trouble (ST), or ischemic colitis before April 2000 were categorized as old thrombotic event (+) group and those with thrombotic events occurring between April 2000 and April 2002 as new thrombotic event (+) group. Patients that died between April 2000 and April 2002 were defined as non-survivors and those surviving during this trial as survivor. We compared the values of the atherosclerosis tests between non-survivors and survivors, between old thrombotic event (+) and old thrombotic event (-) groups, between new thrombotic event (+) and new thrombotic event (-) groups.
Ankle-Arm Blood Pressure Index
Brachial artery blood pressure was measured by standard method with a sphygmomanometer (8) (9) (10) . Ankle blood pressures were then measured using a mercury manometer. An arm pressure cuff was placed just above the malleoli and the systolic pressure was measured. API was calculated as the ratio of the ankle systolic pressure divided by the arm systolic pressure.
Aortic Calcification Index
ACI was measured as follows (11, 12) : The area above the bifurcation of the common iliac artery was scanned 10 times at 1-cm intervals by abdominal computed tomography (CT). The scans were then analyzed to calculate the area of calcification and the cross-sectional area of the abdominal aorta. The calcification area in the abdominal aorta was divided by cross-sectional area of the aorta to express the extent of calcification (12) .
Risk Factors
With the assistance of dialysis nurse, the study patients also completed a written questionnaire on atherosclerotic risk factors such as smoking, diabetes mellitus, hypertension, HD duration, and age.
Hemostatic Markers
Blood samples were collected immediately before HD. Fibrinogen was measured by clotting method, using Multifibren U (Behringwerke AG, Marburg, Germany). Antithrombin (AT) (15) and protein C (PC) activities were measured by amidolytic assays, using a Berichrom-Antithrombin kit (Behringwerke AG) and a Berichrom-Protein C kit (Behringwerke AG). Plasma thrombin-antithrombin complex (TAT), plasminplasmin inhibitor complex (PPIC), D-dimer, TM (14) , tPA-PAI-I complex and soluble fibrin (SF) levels were measured using the following kits: TAT test (16) (Kokusai Shiyaku, Kobe Japan), plasmin-plasmin inhibitor complex (PPIC) test (17) (Kokusai Shiyaku, Kobe Japan), D-dimer test (Kokusai Shiyaku) and SF test (Nissui, Tokyo, Japan). Protein C (PC), protein S (PS) and vWF antigen were measured by enzyme immunoassay using anti-PC, anti-PS and anti-vWF antibodies (DAKO, Denmark).
Data are expressed as the mean ± standard deviation. Statistical difference between two groups was assessed with the Man-Whitney Utest. We used the Kaplan-Meier method to compare the survival time between groups.
RESULTS
In April 2000, there were 36 patients with old thrombotic events among 84 patients. During the follow-up period, 26 patients of the old thrombotic event (+) group and 15 of the old thrombotic event (-) group had new thrombotic events. At the end of study, 41 patients presented new thrombotic events, and except one patient, 15 had thrombosis-associated death. Forty-three patients had no new thrombotic events and 68 survived throughout the study (Fig. 1 ).
Fifteen patients (seven men and eight women, mean age of death 68.1±8.5 years old, mean pe-riod of observation 10.8±8.3 month) died due to thrombotic disease. The cause of death was CAD in eight patients, CVD in four, pulmonary embolism (PE) after operation for atherosclerotic obliterans in two, and ischemic colitis in one patient ( Table 1) . Twenty-five patients who had new thrombotic events survived during the follow-up period, (14 men and 11 women, mean age in onset of event 64.6±11.6 years old, mean period of observation 10±7.7 month). Among these patients, 12 had CAD, 10 ST, three atherosclerotic obliterans, and 2 had CVD ( Table 2) . Table 3 shows the result of atherosclerotic risk factors totals, survivor and non-survivor. The HD duration was significantly longer in non-survivor than in survivor. (9.1±6.4 vs. 6.6±5.6, p<0.01). The BMI was significantly lower in non-survivors than survivors (18.7±2.3 vs. 20.8±3.0, p<0.01). Table 4 shows the results of the hemostatic markers between survivors and non-survivors, and between the new thrombotic event (+) and new thrombotic event (-) groups. There was no significant difference in the hemostatic markers between survivors and non-survivors, or between the new thrombotic event (+) and new thrombotic event (-) groups.
AORTIC CALCIFICATION INDEX AND ANKLE-ARM BLOOD PRESSURE IN
The ACI was significantly higher in the nonsurvivors than in the survivors (0.62±0.27 vs. 0.30±0.22, p<0.001). The API was significantly lower in the non-survivors than in the survivors (0.63±0.43 vs. 1.07±0.29, p<0.001) (Fig. 2) .
The ACI was significantly higher in the new thrombotic event (+) than in the new thrombotic event (-) groups (0.43±0.09 vs. 0.31±0.04, p<0.05). The API was significantly lower in the new thrombotic event (+) than in the new thrombotic event (-) groups (0.89±0.16 vs. 1.10±0.08, p<0.01) (Fig. 3) .
The ACI was significantly higher in the old thrombotic event (+) than in the old thrombotic event (-) groups (0.48±0.26 vs. 0.29±0.24, p<0.001). The API was significantly lower in the old thrombotic event (+) than in the old thrombotic event (-) groups (0.84±0.37 vs. 1.11±0.31, p<0.001) ( Fig. 4 ). Fig. 5 shows the Kaplan-Meier survival curves for API and ACI. Survival rate was significantly less in patients with less than 0.9 of API than in those with more than 0.9 of API (p<0.001) ( Fig.  5A ). There was no significant difference in HD duration or BMI between low API and high API. Data are not shown. Survival rate was significantly lower in patients with high ACI than in those with low ACI (Fig. 5B) . The BMI was sig-nificantly lower in patients with high ACI than in those with low ACI (19.8±3.1 vs. 21.1±2.7, p<0.05).There was no significant difference in HD duration between high ACI and low ACI. (USRDS) reported a 1-year mortality rate of 21.1% (2) . In Japan, the annual crude mortality rate for 1999 was 9.4% (1) . There are some reasons why the mortality of our patients was lower than that of the USRDS report. In the United States, patients with end-stage renal disease (ESRD) who have few risk factors undergo renal transplantation. But patients with ESRD who undergo HD have a higher risk of hypertension, diabetes mellitus, and CAD. Our patients have a low risk factor for thrombosis or were treated well. Causes of death included CAD in eight patients (53.3%), CVD in four (26.7%), and PE after atherosclerotic obliterans surgery in two patients (13.4%). The fact that the main cause of death in the United States was CAD suggests that arteriosclerosis might play an important role in the death rate among patients receiving HD (18) . In our study, the cause of death was due to thrombosis in 93.8%. CAD is still the most important cause of death in patients receiving HD. This trend is expected to continue because many patients receiving HD have DM or hypertension. In the survivors, 25 patients (30%) had new thrombotic events. Thrombotic events were the main cause of death in patients with HD. During this study, two patients died from PE. PE has been considered to be uncommon in HD, but the overall incidence rate of PE was 149/100,000 patients under HD compared with 24.62/100,000 persons in US populations (19) . Because patients under HD are treated with heparin, we should pay more attention to complications occurring after surgical procedures in patients receiving HD. Because patients receiving HD frequently have thrombotic events, we examined the difference of hemostatic factors in patients with HD. However, there was no significant difference in hemostatic markers between survivors and nonsurvivors, or between new thrombotic event (+) and new thrombotic event (-) groups. These findings may be explained by the fact that patients receiving HD are treated with heparin. The BMI was significantly lower in non-survivors than survivors. In US HD-treated patients, a lower BMI is found to be a strong predictor of elevated mortality risk (20) . The relative increase in mortality risk associated with lower BMI is larger in sicker individuals with a history of chronic disease (21) .
There was significant difference in API between survivors and non-survivors, and between patients with and without thrombotic events, suggesting that API is a powerful predictor of morbidity and mortality in patients with HD. In elderly women, it was reported that an API less than 0.9 is a high predictor of cardiovascular mortality (7) . It was also reported that API was an important predictor of cardiovascular mortality in an elderly population with hypertension (22) . The cut-off levels for API were originally determined from studies in patients referred for angiography of the lower extremities. The cut-off level of 0.8 or 0.9 indicated the occurrence of atherosclerosis, high risk, and increased mortality API > 0.9 (8, 22, 23) in our study, the mean value of API in the thrombotic event groups or non-survivor group was under 0.90, suggesting a good accordance with the population study (8, 22, 23) . The API is a useful and easily performed screening test for detecting abnormality in the lower extremity and it remains an excellent indicator of the global arterial circulation of the lower extremity. There was also significant difference in ACI values between survivors and non-survivors, and between patients with and without thrombotic events. Vascular calcification is frequently seen in patients with uremia. Coronary calcification occurs frequently in patients with underlying atherosclerotic disease and it has been shown to be associated with cardiovascular events (24) (25) (26) . Arterial calcification has been reported to be positively correlated with CAD and with increased risk of myocardial infarction and ischemic episodes of ASO. Epidemiologic studies have shown that sclerosis of the abdominal aorta reflects early arteriosclerosis and that it is significantly correlated with coronary arteriosclerosis (24) . The presence of calcification in arteries has been reported to predict the death or myocardial infarction in high-risk and asymptomatic patients (27). Aortosclerosis is significantly accelerated in patients receiving HD and its degree is comparable to that occurring in 20 years older control patients without renal disease (14) .
In conclusion, the result of our present study demonstrated that atherosclerotic markers such as ACI and API are useful for predicting thrombotic events and prognosis in patients receiving HD.
